Intellia Therapeutics, Inc.
NASDAQIntellia Therapeutics enters the back half of June with an unusual tension at its core: short sellers are pulling back, the stock just posted a 13% weekly gain, yet the short score remains deeply elevated and the structural bear case has not shifted. The headline on positioning is the short interest itself — at 41.8% of free float, it is one of the highest readings in US biotech…
Snapshot as of 27 Jun 2026
Intellia Therapeutics enters the back half of June with an unusual tension at its core: short sellers are pulling back, the stock just posted a 13% weekly gain, yet the short score remains deeply elevated and the…
Intellia Therapeutics walks into its Q1 2026 earnings report — due after the close on May 14 — carrying the heaviest short positioning it has seen in weeks and a Street that is rapidly repricing what this gene-editing…
Intellia Therapeutics reports after the close on May 14 with more than a third of its free float sold short — a level that makes the lending market the most important context for tomorrow's print. Short interest has…
Intellia Therapeutics fell 14% Thursday while short interest ticked up to 34.4% of float. Cost to borrow rose 25% week-over-week. ARK and Vanguard added over 2 million shares each in Q1. Analysts hold a Buy consensus…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NTLA — free to start on ORTEX.
Sign up for free →Open NTLA on ORTEX